RT Journal Article
SR Electronic
T1 Breast cancer risks associated with missense variants in breast cancer susceptibility genes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.02.21262369
DO 10.1101/2021.09.02.21262369
A1 Leila Dorling
A1 Sara Carvalho
A1 Jamie Allen
A1 Michael T. Parsons
A1 Cristina Fortuno
A1 Anna González-Neira
A1 Stephan M. Heijl
A1 Muriel A. Adank
A1 Thomas U. Ahearn
A1 Irene L. Andrulis
A1 Päivi Auvinen
A1 Heiko Becher
A1 Matthias W. Beckmann
A1 Sabine Behrens
A1 Marina Bermisheva
A1 Natalia V. Bogdanova
A1 Stig E. Bojesen
A1 Manjeet K. Bolla
A1 Michael Bremer
A1 Ignacio Briceno
A1 Nicola J. Camp
A1 Archie Campbell
A1 Jose E. Castelao
A1 Jenny Chang-Claude
A1 Stephen J. Chanock
A1 Georgia Chenevix-Trench
A1 NBCS Collaborators
A1 J. Margriet Collée
A1 Kamila Czene
A1 Joe Dennis
A1 Thilo Dörk
A1 Mikael Eriksson
A1 D. Gareth Evans
A1 Peter A. Fasching
A1 Jonine Figueroa
A1 Henrik Flyger
A1 Marike Gabrielson
A1 Manuela Gago-Dominguez
A1 Montserrat García-Closas
A1 Graham G. Giles
A1 Gord Glendon
A1 Pascal Guénel
A1 Melanie Gündert
A1 Andreas Hadjisavvas
A1 Eric Hahnen
A1 Per Hall
A1 Ute Hamann
A1 Elaine F. Harkness
A1 Mikael Hartman
A1 Frans B.L. Hogervorst
A1 Antoinette Hollestelle
A1 Reiner Hoppe
A1 Anthony Howell
A1 kConFab Investigators
A1 SGBCC Investigators
A1 Anna Jakubowska
A1 Audrey Jung
A1 Elza Khusnutdinova
A1 Sung-Won Kim
A1 Yon-Dschun Ko
A1 Vessela N. Kristensen
A1 Inge M.M. Lakeman
A1 Jingmei Li
A1 Annika Lindblom
A1 Maria A. Loizidou
A1 Artitaya Lophatananon
A1 Jan Lubiński
A1 Craig Luccarini
A1 Michael J. Madsen
A1 Arto Mannermaa
A1 Mehdi Manoochehri
A1 Sara Margolin
A1 Dimitrios Mavroudis
A1 Roger L. Milne
A1 Nur Aishah Mohd Taib
A1 Kenneth Muir
A1 Heli Nevanlinna
A1 William G. Newman
A1 Jan C. Oosterwijk
A1 Sue K. Park
A1 Paolo Peterlongo
A1 Paolo Radice
A1 Emmanouil Saloustros
A1 Elinor J. Sawyer
A1 Rita K. Schmutzler
A1 Mitul Shah
A1 Xueling Sim
A1 Melissa C. Southey
A1 Harald Surowy
A1 Maija Suvanto
A1 Ian Tomlinson
A1 Diana Torres
A1 Thérèse Truong
A1 Christi J. van Asperen
A1 Regina Waltes
A1 Qin Wang
A1 Xiaohong R. Yang
A1 Paul D.P. Pharoah
A1 Marjanka K. Schmidt
A1 Javier Benitez
A1 Bas Vroling
A1 Alison M. Dunning
A1 Soo Hwang Teo
A1 Anders Kvist
A1 Miguel de la Hoya
A1 Peter Devilee
A1 Amanda B. Spurdle
A1 Maaike P.G. Vreeswijk
A1 Douglas F. Easton
YR 2021
UL http://medrxiv.org/content/early/2021/09/15/2021.09.02.21262369.abstract
AB BACKGROUND Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2 are associated with increased breast cancer risk, but risks associated with missense variants in these genes are uncertain.METHODS Combining 59,639 breast cancer cases and 53,165 controls, we sampled training (80%) and validation (20%) sets to analyze rare missense variants in ATM (1,146 training variants), BRCA1 (644), BRCA2 (1,425), CHEK2 (325) and PALB2 (472). We evaluated breast cancer risks according to five in-silico prediction-of-deleteriousness algorithms, functional protein domain, and frequency, using logistic regression models and also mixture models in which a subset of variants was assumed to be risk-associated.RESULTS The most predictive in-silico algorithms were Helix (BRCA1, BRCA2 and CHEK2) and CADD (ATM). Increased risks appeared restricted to functional protein domains for ATM (FAT and PIK domains) and BRCA1 (RING and BRCT domains). For ATM, BRCA1 and BRCA2, data were compatible with small subsets (approximately 7%, 2% and 0.6%, respectively) of rare missense variants giving similar risk to those of protein truncating variants in the same gene. For CHEK2, data were more consistent with a large fraction (approximately 60%) of rare missense variants giving a lower risk (OR 1.75, 95% CI (1.47-2.08)) than CHEK2 protein truncating variants. There was little evidence for an association with risk for missense variants in PALB2. The best fitting models were well calibrated in the validation set.CONCLUSIONS These results will inform risk prediction models and the selection of candidate variants for functional assays, and could contribute to the clinical reporting of gene panel testing for breast cancer susceptibility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe sequencing and analysis for this project was funded by the European Union's Horizon 2020 Research and Innovation Programme (BRIDGES: grant number 634935) and the Wellcome Trust [grant no: v203477/Z/16/Z]. BCAC co-ordination was additionally funded by the European Union's Horizon 2020 Research and Innovation Programme (BRIDGES: grant number 634935, BCAST: grant number 633784) and by Cancer Research UK [C1287/A16563]. Study specific funding is given in the Supplemental Note. No authors received payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval to use the BCAC data included in this study was given by the Data Access Co-ordinating Committee (concept #672). All contributing BCAC studies were approved by the relevant ethical review boards, details of which can be found in Additional Table 14.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary level genotype data are available via http://bcac.ccge.medschl.cam.ac.uk and in Supplementary Tables 9-13. Individual level data are available via the BCAC Data Access Co-ordinating Committee (bcac@medschl.cam.ac.uk)PTVsProtein truncating variantsVUSVariants of uncertain significanceBCACBreast Cancer Association ConsortiumVEPEnsembl Variant Effect PredictorCADDCombined Annotation Dependent DepletionREVELRare Exome Variant Ensembl LearnerSGESaturation Genome EditingLRLogistic regressionOROdds ratioEMExpectation-maximizationPPPosterior probabilityQ5Fifth quntileLOFSGELoss of functionFUNCSGEFunctionalINTSGEIntermediate functionGWASGenome wide association study